A M&S model was built to offer an alternate approach to dedicated timing studies to determine the best time to vaccinate pregnant women.Read More
Author: Michael Dodds
Mike Dodds has been working in the pharmacometrics field since 2005. He joined Certara (formerly Quantitative Solutions) in 2015 in the role of Director Consulting Services and is based in Seattle, Washington. Previously, he worked for ZymoGenetics in the Department of Pharmacokinetics and Pharmacodynamics, providing predictive modeling support for emerging drug candidates in the areas of autoimmunity, coagulation and oncology. Prior to that, he worked for Amgen in the Department of Pharmacokinetics and Drug Metabolism and then Clinical Pharmacology Modeling and Simulation as a pharmacometrics subject matter expert, providing modeling and simulation expertise to guide development program decisions around target selection, candidate selection, preclinical-to-clinical translation, Phase 1, 2 and 3 dose and regimen selection, and biosimilar development. Mike’s research focuses on the application of pharmacometrics: mathematical models of biology, (patho)-physiology, pharmacology and disease that quantify beneficial and undesirable interactions between drugs and patients to predict outcome [Barrett 2008]. Importantly, accurate and precise quantitative prediction of patient outcome allows for informed drug-development decisions. Mike has authored 20+ peer-reviewed articles, has presented at ACoP, ASCPT, PAGE, and holds two patents. He received his BS in Chemical Engineering and BS in Biochemistry from North Carolina State University, MS in Chemical Engineering from Montana State University, and PhD in Bioengineering from the University of Washington. In his free time, Mike enjoys making wine, playing tabletop games, creating large-scale, interactive, flame effect sculpture and exploring the beautiful Pacific Northwest.